It may not make the New York Times’ Best Seller List, but
the release of the FDA’s new book is certainly noteworthy. The FDA today announced that they’ve published
their first ever edition of the “Purple Book”, a list of licensed biological
products and interchangeable biosimilars.
The organization’s new list will serve a similar role to
that of its counterpart in the pharmaceutical industry, the Orange Book, and
will look to answer questions around the substitutability of products. Many have voiced concerns over the extent to
which biologics and biosimilars will be used interchangeably. Although aimed to replicate the biologics
they’re designed after, biosimilars are not identical to those drugs and
therefore are not necessarily perfect substitutes in all cases.
The FDA has indicated that they will use a four part scale
to categorize the interchangeability:
- • Not similar
- • Similar
- • Highly similar
- • Highly similar with a fingerprint-like similarity
The book is broken up into two sections—biologic products
regulated by the Center for Drug Evaluation and Research (CDER) and those
regulated by the Center for Biologics Evaluation and Research (CBER). Among the
information included in these lists is the date a biologic was licensed, the
product name, the proprietary name and the BLA number.
As we begin to see biosimilar applications roll in, we may
see this list build out rather quickly over the next few years.
You can find the announcement from the FDA here.
We’ll
have more on the latest developments in the biosimilars market at the 15thAnnual Business of Biosimilars meeting.
Join us October 20-22 in Boston, MA. Download the agenda to see what’s on tap.
SAVE
$100. Register here and use code XP1986BLOG.
Follow us on Twitter: @FutureOfBiopharma & @Biosimilars
Join us on LinkedIn
Join us on LinkedIn
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment